 SOUTH PLAINFIELD, N.J. , Sept. 29, 2021 PRNewswire -- PTC Therapeutics, Inc. NASDAQ: PTCT today presented a new analysis of five-year results that shows its novel gene therapy, PTC-AADC, leads to profound improvements in children with aromatic L-Amino acid decarboxylase AADC deficiency, a previously intractable, fatal and devastating rare disorder of the central nervous system.1-4 Children treated with PTC-AADC developed motor function and cognitive skills not previously seen, such as holding up their head, sitting or standing with support and communicating, and these persisted for up to 10 years.1 The transformations we are seeing in the children are remarkable, as they could not even lift their heads before treatment, said Stuart W. 